Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study
•Syn, CgA and CD56 were related to the prognosis of LCNEC.•Adenocarcinoma was the most common combined components for LCNEC.•SCLC chemotherapy regimen is a more effective choice for LCNEC.•Overall survival of combined LCNEC tended to be shorter than pure LCNEC. The 2015 World Health Organization cla...
Gespeichert in:
| Veröffentlicht in: | Lung cancer (Amsterdam, Netherlands) Netherlands), 2020-01, Vol.139, p.118-123 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 123 |
|---|---|
| container_issue | |
| container_start_page | 118 |
| container_title | Lung cancer (Amsterdam, Netherlands) |
| container_volume | 139 |
| creator | Zhang, Jia-Tao Li, Ye Yan, Li-Xu Zhu, Zheng-Fei Dong, Xiao-Rong Chu, Qian Wu, Lin Zhang, Hong-Mei Xu, Chun-Wei Lin, Gen Yu, Zong-Yang Hu, Jie Zhu, Bo Wang, Hui-Juan Yang, Fan Song, Zheng-Bo Han, Zheng-Bo Li, Meng-Xia Lin, Jie Wu, Yi-Long Wang, Jin-Liang Zhong, Wen-Zhao |
| description | •Syn, CgA and CD56 were related to the prognosis of LCNEC.•Adenocarcinoma was the most common combined components for LCNEC.•SCLC chemotherapy regimen is a more effective choice for LCNEC.•Overall survival of combined LCNEC tended to be shorter than pure LCNEC.
The 2015 World Health Organization classification defines pulmonary large-cell neuroendocrine carcinoma (LCNEC) as a high-grade neuroendocrine carcinoma. However, the clinical characteristics and prognostic factors of pure LCNEC and combined LCNEC remain unclear. Hence, we performed a multi-center retrospective study to compare the clinical outcomes of pure versus combined LCNEC.
Data from 381 patients with pulmonary LCNEC admitted to 17 Chinese institutes between 2009 and 2016 were collected retrospectively. Clinical characteristics and prognosis were analyzed among patients receiving adjuvant (adjuvant group; n = 56) and first-line (first-line group; n = 146) chemotherapy, as well as among patients receiving small cell lung cancer (SCLC) and non-SCLC (NSCLC) chemotherapy regimens. The Kaplan-Meier method and multivariable Cox regression were used to identify clinicopathological variables that might influence patient outcomes.
Expression levels of neuroendocrine markers (synaptophysin, chromogranin-A, CD56) were associated with patients’ prognosis in the total study cohort. In the adjuvant group, median disease-free survival was non-significantly longer for SCLC-based regimens than for NSCLC-based regimens (P = 0.112). In the first-line group, median progression-free survival was significantly longer for SCLC-based regimens than for NSCLC-based regimens (11.5 vs. 7.2 months, P = 0.003). Among patients with combined LCNEC, adenocarcinoma was the most common combined component, accounting for 70.0 % of cases. Additionally, median overall survival was non-significantly shorter for combined LCNEC than for pure LCNEC (P = 0.083).
The SCLC regimen is a more effective choice, as either first-line or adjuvant chemotherapy, when compared to the NSCLC regimen for LCNEC treatment. Further studies are needed to clarify the survival differences between patients with pure-, and combined LCNEC. |
| doi_str_mv | 10.1016/j.lungcan.2019.11.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2319499381</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169500219307184</els_id><sourcerecordid>2319499381</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-edab52a9bd1d4a65d414b87cc58bd9e2ac3d7b7fb06d8ed4559c10ea9b0b652b3</originalsourceid><addsrcrecordid>eNqFkcuO1DAQRS0EYpqBTwB5ySbBlcRJzAaNhqc0EhtYW35Uj9xK7ODHjPoX-Grc6oYtq5JK51bVrUvIa2AtMBjfHdql-HujfNsxEC1Ay9jwhOxgnrpm7vvuKdlVTjScse6KvEjpwBhMwMRzctXDNHE2jzvy-6NLm4ouH6nz1CzOO6MWGko2YcVENeZHRE-3EpEqb2lta-fR1s6yBq_ikS4q3mNjcFmoxxIDehtMrBA1Khrnw6re0xu6liW7ivmMkUbMMaQNTXYPSFMu9viSPNurJeGrS70mPz9_-nH7tbn7_uXb7c1dY4Zpzg1apXmnhLZgBzVyO8Cg58kYPmsrsFOmt5Oe9pqNdkY7cC4MMKwCpkfe6f6avD3P3WL4VTBlubp0ul55DCXJrgcxCNHPUFF-Rk09NkXcyy26tXqWwOQpBnmQlxjkKQYJIGsMVffmsqLoFe0_1d-_V-DDGcBq9MFhlMk49Aati_Un0gb3nxV_AH1HoJ4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2319499381</pqid></control><display><type>article</type><title>Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Zhang, Jia-Tao ; Li, Ye ; Yan, Li-Xu ; Zhu, Zheng-Fei ; Dong, Xiao-Rong ; Chu, Qian ; Wu, Lin ; Zhang, Hong-Mei ; Xu, Chun-Wei ; Lin, Gen ; Yu, Zong-Yang ; Hu, Jie ; Zhu, Bo ; Wang, Hui-Juan ; Yang, Fan ; Song, Zheng-Bo ; Han, Zheng-Bo ; Li, Meng-Xia ; Lin, Jie ; Wu, Yi-Long ; Wang, Jin-Liang ; Zhong, Wen-Zhao</creator><creatorcontrib>Zhang, Jia-Tao ; Li, Ye ; Yan, Li-Xu ; Zhu, Zheng-Fei ; Dong, Xiao-Rong ; Chu, Qian ; Wu, Lin ; Zhang, Hong-Mei ; Xu, Chun-Wei ; Lin, Gen ; Yu, Zong-Yang ; Hu, Jie ; Zhu, Bo ; Wang, Hui-Juan ; Yang, Fan ; Song, Zheng-Bo ; Han, Zheng-Bo ; Li, Meng-Xia ; Lin, Jie ; Wu, Yi-Long ; Wang, Jin-Liang ; Zhong, Wen-Zhao</creatorcontrib><description>•Syn, CgA and CD56 were related to the prognosis of LCNEC.•Adenocarcinoma was the most common combined components for LCNEC.•SCLC chemotherapy regimen is a more effective choice for LCNEC.•Overall survival of combined LCNEC tended to be shorter than pure LCNEC.
The 2015 World Health Organization classification defines pulmonary large-cell neuroendocrine carcinoma (LCNEC) as a high-grade neuroendocrine carcinoma. However, the clinical characteristics and prognostic factors of pure LCNEC and combined LCNEC remain unclear. Hence, we performed a multi-center retrospective study to compare the clinical outcomes of pure versus combined LCNEC.
Data from 381 patients with pulmonary LCNEC admitted to 17 Chinese institutes between 2009 and 2016 were collected retrospectively. Clinical characteristics and prognosis were analyzed among patients receiving adjuvant (adjuvant group; n = 56) and first-line (first-line group; n = 146) chemotherapy, as well as among patients receiving small cell lung cancer (SCLC) and non-SCLC (NSCLC) chemotherapy regimens. The Kaplan-Meier method and multivariable Cox regression were used to identify clinicopathological variables that might influence patient outcomes.
Expression levels of neuroendocrine markers (synaptophysin, chromogranin-A, CD56) were associated with patients’ prognosis in the total study cohort. In the adjuvant group, median disease-free survival was non-significantly longer for SCLC-based regimens than for NSCLC-based regimens (P = 0.112). In the first-line group, median progression-free survival was significantly longer for SCLC-based regimens than for NSCLC-based regimens (11.5 vs. 7.2 months, P = 0.003). Among patients with combined LCNEC, adenocarcinoma was the most common combined component, accounting for 70.0 % of cases. Additionally, median overall survival was non-significantly shorter for combined LCNEC than for pure LCNEC (P = 0.083).
The SCLC regimen is a more effective choice, as either first-line or adjuvant chemotherapy, when compared to the NSCLC regimen for LCNEC treatment. Further studies are needed to clarify the survival differences between patients with pure-, and combined LCNEC.</description><identifier>ISSN: 0169-5002</identifier><identifier>EISSN: 1872-8332</identifier><identifier>DOI: 10.1016/j.lungcan.2019.11.004</identifier><identifier>PMID: 31775086</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carcinoma, Large Cell - drug therapy ; Carcinoma, Large Cell - mortality ; Carcinoma, Large Cell - pathology ; Carcinoma, Neuroendocrine - drug therapy ; Carcinoma, Neuroendocrine - mortality ; Carcinoma, Neuroendocrine - pathology ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - pathology ; Chemotherapy ; Combined large cell neuroendocrine carcinoma ; Female ; Follow-Up Studies ; Health Status Disparities ; High-grade neuroendocrine carcinoma ; Humans ; Large cell neuroendocrine carcinoma ; Lung Neoplasms - drug therapy ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Small Cell Lung Carcinoma - drug therapy ; Small Cell Lung Carcinoma - mortality ; Small Cell Lung Carcinoma - pathology ; Survival Rate ; Young Adult</subject><ispartof>Lung cancer (Amsterdam, Netherlands), 2020-01, Vol.139, p.118-123</ispartof><rights>2019 The Authors</rights><rights>Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-edab52a9bd1d4a65d414b87cc58bd9e2ac3d7b7fb06d8ed4559c10ea9b0b652b3</citedby><cites>FETCH-LOGICAL-c478t-edab52a9bd1d4a65d414b87cc58bd9e2ac3d7b7fb06d8ed4559c10ea9b0b652b3</cites><orcidid>0000-0002-8917-8635 ; 0000-0001-6793-552X ; 0000-0002-3611-0258 ; 0000-0001-7537-3619</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0169500219307184$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31775086$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Jia-Tao</creatorcontrib><creatorcontrib>Li, Ye</creatorcontrib><creatorcontrib>Yan, Li-Xu</creatorcontrib><creatorcontrib>Zhu, Zheng-Fei</creatorcontrib><creatorcontrib>Dong, Xiao-Rong</creatorcontrib><creatorcontrib>Chu, Qian</creatorcontrib><creatorcontrib>Wu, Lin</creatorcontrib><creatorcontrib>Zhang, Hong-Mei</creatorcontrib><creatorcontrib>Xu, Chun-Wei</creatorcontrib><creatorcontrib>Lin, Gen</creatorcontrib><creatorcontrib>Yu, Zong-Yang</creatorcontrib><creatorcontrib>Hu, Jie</creatorcontrib><creatorcontrib>Zhu, Bo</creatorcontrib><creatorcontrib>Wang, Hui-Juan</creatorcontrib><creatorcontrib>Yang, Fan</creatorcontrib><creatorcontrib>Song, Zheng-Bo</creatorcontrib><creatorcontrib>Han, Zheng-Bo</creatorcontrib><creatorcontrib>Li, Meng-Xia</creatorcontrib><creatorcontrib>Lin, Jie</creatorcontrib><creatorcontrib>Wu, Yi-Long</creatorcontrib><creatorcontrib>Wang, Jin-Liang</creatorcontrib><creatorcontrib>Zhong, Wen-Zhao</creatorcontrib><title>Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study</title><title>Lung cancer (Amsterdam, Netherlands)</title><addtitle>Lung Cancer</addtitle><description>•Syn, CgA and CD56 were related to the prognosis of LCNEC.•Adenocarcinoma was the most common combined components for LCNEC.•SCLC chemotherapy regimen is a more effective choice for LCNEC.•Overall survival of combined LCNEC tended to be shorter than pure LCNEC.
The 2015 World Health Organization classification defines pulmonary large-cell neuroendocrine carcinoma (LCNEC) as a high-grade neuroendocrine carcinoma. However, the clinical characteristics and prognostic factors of pure LCNEC and combined LCNEC remain unclear. Hence, we performed a multi-center retrospective study to compare the clinical outcomes of pure versus combined LCNEC.
Data from 381 patients with pulmonary LCNEC admitted to 17 Chinese institutes between 2009 and 2016 were collected retrospectively. Clinical characteristics and prognosis were analyzed among patients receiving adjuvant (adjuvant group; n = 56) and first-line (first-line group; n = 146) chemotherapy, as well as among patients receiving small cell lung cancer (SCLC) and non-SCLC (NSCLC) chemotherapy regimens. The Kaplan-Meier method and multivariable Cox regression were used to identify clinicopathological variables that might influence patient outcomes.
Expression levels of neuroendocrine markers (synaptophysin, chromogranin-A, CD56) were associated with patients’ prognosis in the total study cohort. In the adjuvant group, median disease-free survival was non-significantly longer for SCLC-based regimens than for NSCLC-based regimens (P = 0.112). In the first-line group, median progression-free survival was significantly longer for SCLC-based regimens than for NSCLC-based regimens (11.5 vs. 7.2 months, P = 0.003). Among patients with combined LCNEC, adenocarcinoma was the most common combined component, accounting for 70.0 % of cases. Additionally, median overall survival was non-significantly shorter for combined LCNEC than for pure LCNEC (P = 0.083).
The SCLC regimen is a more effective choice, as either first-line or adjuvant chemotherapy, when compared to the NSCLC regimen for LCNEC treatment. Further studies are needed to clarify the survival differences between patients with pure-, and combined LCNEC.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Carcinoma, Large Cell - drug therapy</subject><subject>Carcinoma, Large Cell - mortality</subject><subject>Carcinoma, Large Cell - pathology</subject><subject>Carcinoma, Neuroendocrine - drug therapy</subject><subject>Carcinoma, Neuroendocrine - mortality</subject><subject>Carcinoma, Neuroendocrine - pathology</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Chemotherapy</subject><subject>Combined large cell neuroendocrine carcinoma</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Health Status Disparities</subject><subject>High-grade neuroendocrine carcinoma</subject><subject>Humans</subject><subject>Large cell neuroendocrine carcinoma</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Small Cell Lung Carcinoma - drug therapy</subject><subject>Small Cell Lung Carcinoma - mortality</subject><subject>Small Cell Lung Carcinoma - pathology</subject><subject>Survival Rate</subject><subject>Young Adult</subject><issn>0169-5002</issn><issn>1872-8332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcuO1DAQRS0EYpqBTwB5ySbBlcRJzAaNhqc0EhtYW35Uj9xK7ODHjPoX-Grc6oYtq5JK51bVrUvIa2AtMBjfHdql-HujfNsxEC1Ay9jwhOxgnrpm7vvuKdlVTjScse6KvEjpwBhMwMRzctXDNHE2jzvy-6NLm4ouH6nz1CzOO6MWGko2YcVENeZHRE-3EpEqb2lta-fR1s6yBq_ikS4q3mNjcFmoxxIDehtMrBA1Khrnw6re0xu6liW7ivmMkUbMMaQNTXYPSFMu9viSPNurJeGrS70mPz9_-nH7tbn7_uXb7c1dY4Zpzg1apXmnhLZgBzVyO8Cg58kYPmsrsFOmt5Oe9pqNdkY7cC4MMKwCpkfe6f6avD3P3WL4VTBlubp0ul55DCXJrgcxCNHPUFF-Rk09NkXcyy26tXqWwOQpBnmQlxjkKQYJIGsMVffmsqLoFe0_1d-_V-DDGcBq9MFhlMk49Aati_Un0gb3nxV_AH1HoJ4</recordid><startdate>202001</startdate><enddate>202001</enddate><creator>Zhang, Jia-Tao</creator><creator>Li, Ye</creator><creator>Yan, Li-Xu</creator><creator>Zhu, Zheng-Fei</creator><creator>Dong, Xiao-Rong</creator><creator>Chu, Qian</creator><creator>Wu, Lin</creator><creator>Zhang, Hong-Mei</creator><creator>Xu, Chun-Wei</creator><creator>Lin, Gen</creator><creator>Yu, Zong-Yang</creator><creator>Hu, Jie</creator><creator>Zhu, Bo</creator><creator>Wang, Hui-Juan</creator><creator>Yang, Fan</creator><creator>Song, Zheng-Bo</creator><creator>Han, Zheng-Bo</creator><creator>Li, Meng-Xia</creator><creator>Lin, Jie</creator><creator>Wu, Yi-Long</creator><creator>Wang, Jin-Liang</creator><creator>Zhong, Wen-Zhao</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8917-8635</orcidid><orcidid>https://orcid.org/0000-0001-6793-552X</orcidid><orcidid>https://orcid.org/0000-0002-3611-0258</orcidid><orcidid>https://orcid.org/0000-0001-7537-3619</orcidid></search><sort><creationdate>202001</creationdate><title>Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study</title><author>Zhang, Jia-Tao ; Li, Ye ; Yan, Li-Xu ; Zhu, Zheng-Fei ; Dong, Xiao-Rong ; Chu, Qian ; Wu, Lin ; Zhang, Hong-Mei ; Xu, Chun-Wei ; Lin, Gen ; Yu, Zong-Yang ; Hu, Jie ; Zhu, Bo ; Wang, Hui-Juan ; Yang, Fan ; Song, Zheng-Bo ; Han, Zheng-Bo ; Li, Meng-Xia ; Lin, Jie ; Wu, Yi-Long ; Wang, Jin-Liang ; Zhong, Wen-Zhao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-edab52a9bd1d4a65d414b87cc58bd9e2ac3d7b7fb06d8ed4559c10ea9b0b652b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Carcinoma, Large Cell - drug therapy</topic><topic>Carcinoma, Large Cell - mortality</topic><topic>Carcinoma, Large Cell - pathology</topic><topic>Carcinoma, Neuroendocrine - drug therapy</topic><topic>Carcinoma, Neuroendocrine - mortality</topic><topic>Carcinoma, Neuroendocrine - pathology</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Chemotherapy</topic><topic>Combined large cell neuroendocrine carcinoma</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Health Status Disparities</topic><topic>High-grade neuroendocrine carcinoma</topic><topic>Humans</topic><topic>Large cell neuroendocrine carcinoma</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Small Cell Lung Carcinoma - drug therapy</topic><topic>Small Cell Lung Carcinoma - mortality</topic><topic>Small Cell Lung Carcinoma - pathology</topic><topic>Survival Rate</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Jia-Tao</creatorcontrib><creatorcontrib>Li, Ye</creatorcontrib><creatorcontrib>Yan, Li-Xu</creatorcontrib><creatorcontrib>Zhu, Zheng-Fei</creatorcontrib><creatorcontrib>Dong, Xiao-Rong</creatorcontrib><creatorcontrib>Chu, Qian</creatorcontrib><creatorcontrib>Wu, Lin</creatorcontrib><creatorcontrib>Zhang, Hong-Mei</creatorcontrib><creatorcontrib>Xu, Chun-Wei</creatorcontrib><creatorcontrib>Lin, Gen</creatorcontrib><creatorcontrib>Yu, Zong-Yang</creatorcontrib><creatorcontrib>Hu, Jie</creatorcontrib><creatorcontrib>Zhu, Bo</creatorcontrib><creatorcontrib>Wang, Hui-Juan</creatorcontrib><creatorcontrib>Yang, Fan</creatorcontrib><creatorcontrib>Song, Zheng-Bo</creatorcontrib><creatorcontrib>Han, Zheng-Bo</creatorcontrib><creatorcontrib>Li, Meng-Xia</creatorcontrib><creatorcontrib>Lin, Jie</creatorcontrib><creatorcontrib>Wu, Yi-Long</creatorcontrib><creatorcontrib>Wang, Jin-Liang</creatorcontrib><creatorcontrib>Zhong, Wen-Zhao</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Jia-Tao</au><au>Li, Ye</au><au>Yan, Li-Xu</au><au>Zhu, Zheng-Fei</au><au>Dong, Xiao-Rong</au><au>Chu, Qian</au><au>Wu, Lin</au><au>Zhang, Hong-Mei</au><au>Xu, Chun-Wei</au><au>Lin, Gen</au><au>Yu, Zong-Yang</au><au>Hu, Jie</au><au>Zhu, Bo</au><au>Wang, Hui-Juan</au><au>Yang, Fan</au><au>Song, Zheng-Bo</au><au>Han, Zheng-Bo</au><au>Li, Meng-Xia</au><au>Lin, Jie</au><au>Wu, Yi-Long</au><au>Wang, Jin-Liang</au><au>Zhong, Wen-Zhao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study</atitle><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle><addtitle>Lung Cancer</addtitle><date>2020-01</date><risdate>2020</risdate><volume>139</volume><spage>118</spage><epage>123</epage><pages>118-123</pages><issn>0169-5002</issn><eissn>1872-8332</eissn><abstract>•Syn, CgA and CD56 were related to the prognosis of LCNEC.•Adenocarcinoma was the most common combined components for LCNEC.•SCLC chemotherapy regimen is a more effective choice for LCNEC.•Overall survival of combined LCNEC tended to be shorter than pure LCNEC.
The 2015 World Health Organization classification defines pulmonary large-cell neuroendocrine carcinoma (LCNEC) as a high-grade neuroendocrine carcinoma. However, the clinical characteristics and prognostic factors of pure LCNEC and combined LCNEC remain unclear. Hence, we performed a multi-center retrospective study to compare the clinical outcomes of pure versus combined LCNEC.
Data from 381 patients with pulmonary LCNEC admitted to 17 Chinese institutes between 2009 and 2016 were collected retrospectively. Clinical characteristics and prognosis were analyzed among patients receiving adjuvant (adjuvant group; n = 56) and first-line (first-line group; n = 146) chemotherapy, as well as among patients receiving small cell lung cancer (SCLC) and non-SCLC (NSCLC) chemotherapy regimens. The Kaplan-Meier method and multivariable Cox regression were used to identify clinicopathological variables that might influence patient outcomes.
Expression levels of neuroendocrine markers (synaptophysin, chromogranin-A, CD56) were associated with patients’ prognosis in the total study cohort. In the adjuvant group, median disease-free survival was non-significantly longer for SCLC-based regimens than for NSCLC-based regimens (P = 0.112). In the first-line group, median progression-free survival was significantly longer for SCLC-based regimens than for NSCLC-based regimens (11.5 vs. 7.2 months, P = 0.003). Among patients with combined LCNEC, adenocarcinoma was the most common combined component, accounting for 70.0 % of cases. Additionally, median overall survival was non-significantly shorter for combined LCNEC than for pure LCNEC (P = 0.083).
The SCLC regimen is a more effective choice, as either first-line or adjuvant chemotherapy, when compared to the NSCLC regimen for LCNEC treatment. Further studies are needed to clarify the survival differences between patients with pure-, and combined LCNEC.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>31775086</pmid><doi>10.1016/j.lungcan.2019.11.004</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-8917-8635</orcidid><orcidid>https://orcid.org/0000-0001-6793-552X</orcidid><orcidid>https://orcid.org/0000-0002-3611-0258</orcidid><orcidid>https://orcid.org/0000-0001-7537-3619</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0169-5002 |
| ispartof | Lung cancer (Amsterdam, Netherlands), 2020-01, Vol.139, p.118-123 |
| issn | 0169-5002 1872-8332 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2319499381 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Large Cell - drug therapy Carcinoma, Large Cell - mortality Carcinoma, Large Cell - pathology Carcinoma, Neuroendocrine - drug therapy Carcinoma, Neuroendocrine - mortality Carcinoma, Neuroendocrine - pathology Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Chemotherapy Combined large cell neuroendocrine carcinoma Female Follow-Up Studies Health Status Disparities High-grade neuroendocrine carcinoma Humans Large cell neuroendocrine carcinoma Lung Neoplasms - drug therapy Lung Neoplasms - mortality Lung Neoplasms - pathology Male Middle Aged Prognosis Retrospective Studies Small Cell Lung Carcinoma - drug therapy Small Cell Lung Carcinoma - mortality Small Cell Lung Carcinoma - pathology Survival Rate Young Adult |
| title | Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T05%3A57%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Disparity%20in%20clinical%20outcomes%20between%20pure%20and%20combined%20pulmonary%20large-cell%20neuroendocrine%20carcinoma:%20A%20multi-center%20retrospective%20study&rft.jtitle=Lung%20cancer%20(Amsterdam,%20Netherlands)&rft.au=Zhang,%20Jia-Tao&rft.date=2020-01&rft.volume=139&rft.spage=118&rft.epage=123&rft.pages=118-123&rft.issn=0169-5002&rft.eissn=1872-8332&rft_id=info:doi/10.1016/j.lungcan.2019.11.004&rft_dat=%3Cproquest_cross%3E2319499381%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2319499381&rft_id=info:pmid/31775086&rft_els_id=S0169500219307184&rfr_iscdi=true |